PharVision Advisers’s Idexx Laboratories IDXX Stock Holding History

PharVision Advisers’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-463	Closed	-$313K	–	360
2025 Q4	$313K	Buy	+463	New	+$315K	0.16%	246

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's IDXX Position: Q1 2026 in Review

PharVision Advisers sold out of Idexx Laboratories (IDXX) in Q1 2026, closing a stake of 463 shares — an estimated $313K sold.

PharVision Advisers first reported a position in IDXX in Q4 2025 and held it in 1 quarter. The position peaked at $313K in Q4 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

PharVision Advisers reported no remaining Idexx Laboratories position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 463 Idexx Laboratories shares in Q1 2026, an estimated $313K.
PharVision Advisers first reported a position in Idexx Laboratories in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Idexx Laboratories position peaked at $313K in Q4 2025.
1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.